Arquivos do dia: Outubro 18, 2021
Estudo randomizado embasa o uso de heparina em dose terapêutica para pacientes não críticos internados por Covid-19.
18 Out, 2021 | 08:57hEstudos relacionados (alguns resultados conflitantes)
Comentário no Twitter
What are the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital? #BMJResearch by @sholzberg and colleagues.
Includes a #VisualAbstract summarising the study #BMJInfographichttps://t.co/82VisuBKSU pic.twitter.com/b06TdIJvLX
— The BMJ (@bmj_latest) October 15, 2021
Vacina da J&J contra COVID-19: FDA recomenda dose de reforço para adultos acima de 18 anos pelo menos 2 meses depois da vacinação com dose única.
18 Out, 2021 | 08:55hComunicado de imprensa: Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
Comentários:
FDA panel endorses booster shot for J&J COVID-19 vaccine – Associated Press
FDA advisers recommend J&J Covid-19 vaccine boosters, talk mix and match boosters – CNN
Conteúdo relacionado: [Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.
Revisão | Dose de SARS-CoV-2, infecção e desfechos de doença para COVID-19.
18 Out, 2021 | 08:53hConteúdo relacionado: Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19.
Comentário do autor no Twitter (fio – clique para saber mais)
SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 – A Review @brosseau_lisa @KevinEscandonMD @AngelaKUlrich @angie_rasmussen Chad Roy @neuronerdsunite @SaskiaPopescu @mtosterholm
https://t.co/2rv0oH1OM5
Quick 🧵 1/ @CIDRAP @acinnacional pic.twitter.com/7lnNYu6eto— Kevin Escandón MD MSc (@KevinEscandonMD) October 15, 2021
[Preprint] Avanço das infecções por SARS-CoV-2 em 620.000 veteranos americanos, de 1/2/2021 a 13/8/2021 – “A proteção da vacina diminuiu de 91,9% em março para 53,9% em meados de agosto.”
18 Out, 2021 | 08:51hConteúdos relacionados:
Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.
COVID vaccine effects wane over time but still prevent death and severe illness.
Perspective | What we actually know about waning immunity.
Another study shows Pfizer mRNA vaccine immunity is reduced over time.
Studies: COVID vaccine protection waning against infection but not hospitalization.
Comentário no Twitter
New on breakthrough infections in 620,000 Veterans
"Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%"https://t.co/xonBb4aEqJ highest reduction with J&J vaccine pic.twitter.com/rbhXOREFPP— Eric Topol (@EricTopol) October 15, 2021
Oito meses depois: pesquisadores comparam as respostas imunes elicitadas por 3 vacinas contra COVID-19.
18 Out, 2021 | 08:50hComunicado de imprensa: Eight months later: Researchers compare immune responses elicited by three COVID-19 vaccines – Beth Israel Deaconess Medical Center
Estudo original: Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines – New England Journal of Medicine
Comentário no Twitter
Just published @NEJM
Neutralizing antibody levels and T cells response out to 8 months for Pfizer, Moderna and J&J vaccines https://t.co/ghAgk3Y4kR
Moderna highest antibody response; J&J while lower doesn't fall off and best CD8 T-cell response at 8 months pic.twitter.com/uANSzAylMF— Eric Topol (@EricTopol) October 15, 2021
O que as máscaras podem fazer? Parte 2 | O que é preciso para se realizar um bom estudo sobre máscaras – e por que a maioria falha.
18 Out, 2021 | 08:48hCOMMENTARY: What can masks do? Part 2: What makes for a good mask study — and why most fail – CIDRAP
Ver também: COMMENTARY: What can masks do? Part 1: The science behind COVID-19 protection – CIDRAP
Tratamento do diabetes melito em pacientes com doença renal crônica: Core Curriculum 2022.
18 Out, 2021 | 08:47hDiretrizes para anestesiologistas sobre o manejo do sangue do paciente em cirurgia cardíaca.
18 Out, 2021 | 08:46h
Comentário no Twitter
Please check out editorial on patient #blood management in #cardiacsurgery, a collaboration between Society of Thoracic Surgeons, Society of Cardiovascular Anestheisologists and SABM, AmSECT. https://t.co/HHA8SjxNot pic.twitter.com/DAj2TrGYC3
— Jiapeng Huang (@jiapenghuang) September 24, 2021
Diretrizes para a abordagem cirúrgica da retocolite ulcerativa.
18 Out, 2021 | 08:44h
Comentário no Twitter
@ASCRS_1 Clinical Practice Guidelines – Surgical Management of #UlcerativeColiltis – what do you think? https://t.co/om9IBPoO5S@HolubarStefan @AmyLightnerMD @VitaliyPoylin @JonVogel7 @BradleyDavisMD @UmaMahadevanIBD @DrSamirAShah1 @SunandaKaneMD @ScottRSteeleMD @ianmpaquette pic.twitter.com/D2eywXrATE
— DCRjournal (@DCRjournal) July 9, 2021
Ponto de vista | Excesso de tratamento cirúrgico e tomada de decisão compartilhada – Os limites da escolha. “Modelos de pagamento incentivam ainda mais a intervenção cirúrgica. Planos de pagamento por serviço premiam cirurgiões por operação, e não por garantirem que aquela cirurgia é a ideal para o paciente.”
18 Out, 2021 | 08:43hSurgical Overtreatment and Shared Decision-making—The Limits of Choice – JAMA Surgery (gratuito por tempo limitado)
Comentário no Twitter
“Adjusting payment models to mitigate financial incentives..to overtreat is a start. However..greater focus should be given to the myriad other causes of overtreatment,” such as triggers of care cascades, write Clapp, Schwarze & @LeeAFleisher. https://t.co/f4mPsnxyVB
— Ben Harder #BlackLivesMatter (@benharder) October 14, 2021